A new era for Waldenstrom macroglobulinemia: MYD88 L265P
- 30 May 2013
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 121 (22), 4434-4436
- https://doi.org/10.1182/blood-2013-04-494849
Abstract
In this issue of Blood, Poulain et al demonstrate the high prevalence of the MYD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight into its biological relevance in the growth and survival of WM.1This publication has 9 references indexed in Scilit:
- MYD88 L265P mutation in Waldenstrom macroglobulinemiaBlood, 2013
- Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasmsBlood, 2013
- MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionBlood, 2013
- MYD88 L265P Somatic Mutation in IgM MGUSThe New England Journal of Medicine, 2012
- MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.Blood, 2012
- IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomasLeukemia, 2012
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaThe New England Journal of Medicine, 2012
- Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors.Journal of Clinical Oncology, 2012
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010